Evolution and emergence of a new era of antiviral treatment for chronic hepatitis C infection

International Journal of Antimicrobial Agents

Volumn 43, Issue 1, 2014, Pages 17-25

  Lim, T R ^a   Tan, B H ^b   Mutimer, D J ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Antiviral treatment; Directly acting antiviral; Hepatitis C

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; BOCEPREVIR; DEB 025; FALDAPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; ANORECTAL DISEASE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MORBIDITY; MORTALITY; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS LOAD;

ANTIVIRAL TREATMENT; DIRECTLY ACTING ANTIVIRAL; HEPATITIS C;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROLINE;

EID: 84890799386     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.09.008     Document Type: Review

References (75)

1. J.F. Perz, G.L. Armstrong, L.A. Farrington, Y.J. Hutin, and B.P. Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
2. Health Protection Agency Hepatitis C in the UK, 2011 report 2011 HPA London, UK
3. G. Fattovich, G. Giustina, F. Degos, F. Tremolada, G. Diodati, and P. Almasio Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
4. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
5. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
6. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotypes 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
7. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
8. J.M. Timpe, and J.A. McKeating Hepatitis C virus entry: possible targets for therapy Gut 57 2008 1728 1737
9. M. Kurosaki, N. Enomoto, F. Marumo, and C. Sato Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection Hepatology 18 1993 1293 1299
10. J. Bukh, R.H. Miller, and R.H. Purcell Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes Semin Liver Dis 15 1995 41 63
11. J.M. Gottwein, T.K. Scheel, T.B. Jensen, J.B. Lademann, J.C. Prentoe, and M.L. Knudsen Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs Hepatology 49 2009 364 377
12. P. Simmonds Clinical relevance of hepatitis C virus genotypes Gut 40 1997 291 293
13. C. Cammà, M. Giunta, G. Pinzello, A. Morabito, P. Verderio, and L. Pagliaro Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials Am J Gastroenterol 94 1999 581 595
14. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, and V.K. Rustgi Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N Engl J Med 339 1998 1485 1492
15. T. Poynard, P. Marcellin, S.S. Lee, C. Niederau, G.S. Minuk, and G. Ideo Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426 1432
16. A.M. Di Bisceglie, H.S. Conjeevaram, M.W. Fried, R. Sallie, Y. Park, and C. Yurdaydin Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial Ann Intern Med 123 1995 897 903
17. E.J. Heathcote, M.L. Shiffman, W.G. Cooksley, G.M. Dusheiko, S.S. Lee, and L. Balart Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis N Engl J Med 343 2000 1673 1680
18. S. Zeuzem, S.V. Feinman, J. Rasenack, E.J. Heathcote, M.Y. Lai, and E. Gane Peginterferon alfa-2a in patients with chronic hepatitis C N Engl J Med 343 2000 1666 1672
19. M.G. Ghany, D.B. Strader, D.L. Thomas, L.B. Seeff, and American Association for the Study of Liver Diseases Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
20. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Gonçales Jr. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
21. G.L. Davis, J.B. Wong, J.G. McHutchison, M.P. Manns, J. Harvey, and J. Albrecht Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 2003 645 652
22. O. Reichard, G. Norkrans, A. Frydén, J.H. Braconier, A. Sönnerborg, and O. Weiland Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C Lancet 351 1998 83 87
23. J.M. Pawlotsky, H. Dahari, A.U. Neumann, C. Hezode, G. Germanidis, and I. Lonjon Antiviral action of ribavirin in chronic hepatitis C Gastroenterology 126 2004 703 714
24. M.L. Shiffman, F. Suter, B.R. Bacon, D. Nelson, H. Harley, and R. Solá Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3 N Engl J Med 357 2007 124 134
25. A.J. Muir, K.Q. Hu, S.C. Gordon, K. Koury, N. Boparai, and S. Noviello Hepatitis C treatment among racial and ethnic groups in the IDEAL trial J Viral Hepat 18 2011 e134 e143
26. S. Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140 2004 370 381
27. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593 [Erratum in: N Engl J Med 2009;361:1027]
28. D. Ge, J. Fellay, A.J. Thompson, J.S. Simon, K.V. Shianna, and T.J. Urban Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
29. P. Ferenci, M.W. Fried, M.L. Shiffman, C.I. Smith, G. Marinos, and F.L. Gonçales Jr. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 kD)/ribavirin J Hepatol 43 2005 425 433
30. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
31. M. Diago, M.L. Shiffman, J.P. Bronowicki, S. Zeuzem, M. Rodriguez-Torres, and S.C. Pappas Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40 kD) plus ribavirin Hepatology 51 2010 1897 1903
32. P. Ferenci, H. Laferl, T.M. Scherzer, M. Gschwantler, A. Maieron, and H. Brunner Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2008 451 458
33. M.L. Yu, C.Y. Dai, J.F. Huang, C.F. Chiu, Y.H. Yang, and N.J. Hou Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial Hepatology 47 2008 1884 1893
34. A. Mangia, N. Minerva, D. Bacca, R. Cozzolongo, G.L. Ricci, and V. Carretta Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50
35. C.B. Bigger, B. Guerra, K.M. Brasky, G. Hubbard, M.R. Beard, and B.A. Luxon Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees J Virol 78 2004 13779 13792
36. A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brideau, L. Supekova, and R. Thimme Genomic analysis of the host response to hepatitis C virus infection Proc Natl Acad Sci U S A 99 2002 15669 15674
37. M. Gale Jr., and E.M. Foy Evasion of intracellular host defence by hepatitis C virus Nature 436 2005 939 945
38. Y. Liang, H. Ishida, O. Lenz, T.I. Lin, O. Nyanguile, and K. Simmen Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors Gastroenterology 135 2008 1710-8.e2
39. K. Morikawa, C.M. Lange, J. Gouttenoire, E. Meylan, V. Brass, and F. Penin Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus J Viral Hepat 18 2011 305 315
40. R.B. Perni, S.J. Almquist, R.A. Byrn, G. Chandorkar, P.R. Chaturvedi, and L.F. Courtney Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob Agents Chemother 50 2006 899 909
41. H.W. Reesink, S. Zeuzem, C.J. Weegink, N. Forestier, A. van Vliet, and J. van de Wetering de Rooij Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study Gastroenterology 131 2006 997 1002
42. N. Forestier, H.W. Reesink, C.J. Weegink, L. McNair, T.L. Kieffer, and H.M. Chu Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C Hepatology 46 2007 640 648
43. T.L. Kieffer, C. Sarrazin, J.S. Miller, M.W. Welker, N. Forestier, and H.W. Reesink Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients Hepatology 46 2007 631 639
44. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment for hepatitis C virus infection N Engl J Med 365 2011 1014 1024
45. A.G. Singal, A.K. Waljee, M. Shiffman, B.R. Bacon, and P.S. Schoenfeld Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy Aliment Pharmacol Ther 32 2010 969 983
46. G.R. Foster, S. Zeuzem, P. Andreone, S. Pol, E.J. Lawitz, and M. Diago Subanalyses of the telaprevir lead-in arm in the REALIZE study: response at Week 4 is not a substitute for prior null response categorization J Hepatol 54 Suppl. 1 2011 S3 S4
47. B.A. Malcolm, R. Liu, F. Lahser, S. Agrawal, B. Belanger, and N. Butkiewicz SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells Antimicrob Agents Chemother 50 2006 1013 1020
48. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
49. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
50. ® (boceprevir) product monograph 2011 Merck & Co. Whitehouse Station, NJ
51. Vertex Pharmaceuticals Inc. Incivek (telaprevir) product monograph 2011 Vertex Pharmaceuticals Inc. Cambridge, MA
52. P. Ferenci, T. Asselah, G.R. Foster, Z. Zeuzem, C. Sarrazin, and C. Moreno Faldaprevir plus pegylated interferon alfa-2a and ribavirin in chronic HCV genotype-1 treatment-naïve patients: final results from STARTVerso1, a randomised, double-blind, placebo controlled phase III trial 47th annual meeting of the European Association for the Study of the Liver 18-22 April 2012; Barcelona, Spain. Geneva 2012 EASL Switzerland [abstract 1416]
53. M. Manns, P. Marcellin, F. Poordad, A. Stanislau Affonso de Araujo, M. Buti, and Y. Horsmans Simeprevir (TMC425) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase II trial 47th annual meeting of the European Association for the Study of the Liver 18-22 April 2012; Barcelona, Spain 2012 EASL Geneva, Switzerland [abstract 1413]
54. I. Jacobson, G.J. Dore, G.R. Foster, M. Fried, M. Radu, and V. Rafalskiy Simeprevir (TMC425) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase II trial 47th annual meeting of the European Association for the Study of the Liver 18-22 April 2012; Barcelona, Spain 2012 EASL Geneva, Switzerland [abstract 1425]
55. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 2405 2416
56. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
57. P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Des Dev Ther 7 2013 105 115
58. R. Flisiak, J.M. Pawlotsky, R. Crabbe, P. Calistru, W. Kryczka, and D. Haussinger Once daily alisporivir (DEB025) plus peginalpha2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naive patients J Hepatol 54 S2 2011 [abstract 190]
59. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
60. F. Poordad, E. Lawitz, K.V. Kowdley, D.E. Cohen, T. Podsadecki, and S. Siggelkow Exploratory study of oral combination antiviral therapy for hepatitis C N Engl J Med 368 2013 45 53
61. S. Zeuzem, T. Asselah, V. Soriano, J.P. Bronowicki, A. Lohse, and B. Mullhaupl Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS 5B inhibitor BI 207127 ± ribavirin (R): final results of SOUND-C2 and predictors of response 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract 232]
62. M.S. Sulkowski, D.F. Gardiner, M. Rodriquez-Torres, K. Reddy, T. Hassanein, and I. Jacobson High rate of sustained virologic response with the all-oral combination of daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naive patients chronically infected with HCV genotype 1, 2, or 3 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract LB-2]
63. G.T. Everson, K.D. Sims, M. Rodriguez-Torres, C. Hezode, E. Lawitz, and M. Bourliere An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 yielded SVR4 of 94% in treatment-naive patients with genotype (GT) 1 chronic hepatitis C virus (HCV) infection 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract LB-3]
64. A.S. Lok, D. Gardiner, E. Lawitz, C. Martorell, G. Everson, and R. Ghalib Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV) Hepatology 56 Suppl. 2012 230A
65. I.M. Jacobson, M.S. Sulkowski, E.J. Gane, M. Koziel, C. de Souza, and T. Kieffer VX-222, telaprevir, and ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C: results of the ZENITH study interferon-free regimen 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract 231]
66. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
67. P. Sharma, and A.S. Lok Interferon-free treatment regimens for hepatitis C: are we there yet? Gastroenterology 141 2011 1963 1967
68. L. Rong, H. Dahari, R.M. Ribeiro, and A.S. Perelson Rapid emergence of protease inhibitor resistance in hepatitis C virus Sci Transl Med 2 2010 30ra32
69. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
70. Y. Suzuki, K. Ikeda, F. Suzuki, J. Toyota, Y. Karino, and K. Chayama Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J Hepatol 58 2013 655 662
71. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
72. P. Marcellin, C. Cooper, L. Balart, D. Larrey, T. Box, and E. Yoshida Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virsu genotype 1 infection Gastroenterology 145 2013 790 800
73. I.M. Jacobson, D.M. Jensen, S. Pol, G. Foster, J. Feld, and E. Yoshida Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alfa-2a (40 kD), and ribavirin with or without mericitabine in HCV genotype 1-infected treatment-experienced patients with advanced hepatic fibrosis: the MATTERHORN study 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA
74. E.J. Gane ELECTRON: Sofosbuvir, GS-5885, and RBV in noncirrhotic pts with GT1 HCV 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract 229]
75. J.V. Kowdley, E. Lawitz, F. Poordad, D.E. Cohen, D. Nelson, and S. Zeuzem A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection 63rd annual meeting of the American Association for the Study of Liver Diseases 9-13 November 2012; Boston, MA 2012 AASLD Alexandria, VA [abstract LB-1]